Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 6;24(1):244.
doi: 10.1186/s12894-024-01634-1.

MicroRNA in prostate cancer: from biogenesis to applicative potential

Affiliations
Review

MicroRNA in prostate cancer: from biogenesis to applicative potential

Xu Luo et al. BMC Urol. .

Abstract

Prostate cancer is the most common solid malignant tumor in men, characterized by high morbidity and mortality. While current screening tools, such as prostate-specific antigen (PSA) testing and digital rectal examination, are available for early detection of prostate cancer, their sensitivity and specificity are limited. Tissue puncture biopsy, although capable of offering a definitive diagnosis, has poor positive predictive rates and burdens the patient more. Therefore, more reliable molecular diagnostic tools for prostate cancer urgently need to be developed. In recent years, microRNAs (miRNAs) have attracted much attention in prostate cancer research. miRNAs are extensively engaged in biological processes such as cell proliferation, differentiation, apoptosis, migration, and invasion by modulating gene expression post-transcriptionally. Dysregulation of miRNA expression in cancer is considered a critical factor in tumorigenesis and progression. This review first briefly introduces the biogenesis of miRNAs and their functions in cancer, then focuses on tumor-promoting miRNAs and tumor-suppressor miRNAs in prostate cancer. Finally, the potential application of miRNAs as multifunctional tools for cancer diagnosis, prognostic assessment, and therapy is discussed in detail. The concluding section summarizes the major points of the review and the challenges ahead.

Keywords: Biomarkers; Diagnosis; MicroRNAs; Prognosis; Prostate cancer; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic illustration of intracellular miRNA biogenesis and action mechanisms. Reproduced with permission from Ref [60]. copyright 2015, Springer Nature

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708. - PubMed
    1. Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562–72. 10.1038/s41585-022-00638-6. - PubMed
    1. Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–40. 10.1101/gad.315739.118. - PMC - PubMed
    1. Mumuni S, O’Donnell C, Doody O. The risk factors and screening uptake for prostate cancer: a scoping review. Healthc (Basel). 2023;11(20):2780. 10.3390/healthcare11202780. - PMC - PubMed
    1. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3–12. 10.1016/j.urology.2003.10.013. - PubMed